A combination of ipilimumab and nivolumab has a significant impact on the five year median overall survival and progression free survival of patients with advanced melanoma compared to either drug alone, the latest analysis from CheckMate 067 shows. The Phase III study randomised 945 patients with previously untreated stage III or IV melanoma in a 1:1:1 ...
Combination immunotherapy boosts melanoma survival: CheckMate067
By Nicola Garrett
28 Sep 2019